HOME >> MEDICINE >> NEWS
Stents that release medication appear more effective than traditional stents

A type of coronary artery stent that releases a medication appears to result in better outcomes than traditional stents for heart attack patients, according to a study in the May 4 issue of JAMA.

Sirolimus, a substance that is thought to help prevent reclosure of coronary arteries, can be released from certain types of stents (metal devices inserted to keep a coronary artery open after angioplasty) to greatly reduce the need for target-vessel revascularization (TVR) compared with bare-metal stents (i.e., stents without medication), according to background information in the article. These drug-eluting stents have the potential to further improve long-term clinical outcome after primary percutaneous coronary intervention (PCI), such as angioplasty. However, the lack of randomized trials to assess the safety and long-term efficacy of sirolimus-eluting stent implantation in patients with acute ST-segment elevation (a certain measurement on an electrocardiogram) myocardial infarction (STEMI), in conjunction with the expected financial consequences, currently limit use of sirolimus-eluting stents in this setting. Current clinical guidelines specifically recommend the drug abciximab during primary PCI. At current European list prices, the use of the drug tirofiban instead of abciximab would absorb the difference in cost between stenting with sirolimus-eluting vs. bare-metal stents.

Marco Valgimigli, M.D., of the University of Ferrara, Italy and colleagues compared angiographic and clinical outcomes for the treatments of high-dose tirofiban plus sirolimus-eluting stenting vs. a current preferred strategy for STEMI treatment, pretreatment with abciximab plus bare-metal stenting. The STRATEGY trial included 175 patients presenting to a single referral center in Italy with STEMI or presumed new left bundle-branch block between March 6, 2003 and April 23, 2004. Patients received either tirofiban regimen plus sirolimus-eluting stenting (n = 87) or abciximab pl
'"/>

Contact: Marco Valgimigli
vlgmrc@unife.it
JAMA and Archives Journals
3-May-2005


Page: 1 2 3

Related medicine news :

1. ACC/AHA release revised UA/NSTEMI guidelines
2. NIAID releases MDR/XDR Tuberculosis research agenda
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. JRRD releases single-topic issue on pain and pain management
5. New prostate cancer clinical guidelines to be released
6. Physicians should be able to review performance rates before release
7. New reflux guidelines released
8. Groundbreaking principles on sexual orientation and human rights released
9. American College of Physicians releases new patient education resources
10. Joint Principles of PC-MH released by organizations representing more than 300,000 physicians
11. Slow-release morphine reduces level of intractable cough

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, ... ” (published by Xlibris on July of 2014). This book details the recent advances ... methodological approaches that benefit people who have lost all of their natural teeth ...
(Date:9/19/2017)... PA (PRWEB) , ... September 19, 2017 , ... ... orthopedic dog beds, has been officially recognized for its September 2016 donation of ... , The company recently received three awards and honors for its contribution from ...
(Date:9/19/2017)... Montclair, NJ (PRWEB) , ... September 19, 2017 ... ... fall following the success of the annual PAINWeek National Conference. On October 7, ... will be an educational and exciting program providing busy clinicians and allied healthcare ...
(Date:9/19/2017)... ... 19, 2017 , ... Bone Solutions Inc. (BSI), an orthobiologics ... medical device, OsteoCrete®. OsteoCrete® bone void filler is designed to assist with bone ... a critical property for bone health and development. , “We’re excited to bring ...
(Date:9/19/2017)... ... September 19, 2017 , ... Premiere Long Island dental office Gold ... named one of the best dentists in America under age 40 by Incisal Edge ... Every fall, the magazine features the best 40 dentists under the age of 40 ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ... on the development of oral drug delivery systems, announced ... the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, ... At the meeting, the FDA gave ... ORMD-0801, would be a Biologics License Application (BLA).  Such ...
(Date:9/1/2017)... N.J. , Sept. 1, 2017  Bayer will present ... the European Society for Medical Oncology (ESMO) 2017 Congress, September ... presented will include new preclinical and clinical data on Bayer,s ... two earlier pipeline projects. ... the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... Aug. 29, 2017 In a move that ... regulatory compliance for veterinary practices of all sizes, Cubex ... partnership that makes TITAN,s expertise in physical security, drug ... Cubex,s clients nationally. ... handling controlled substances is at risk today," said TITAN ...
Breaking Medicine Technology:
Cached News: